A phase II clinical trial utilizes BMS-813160, a CCR2/5-inhibitor, in combination with nivolumab to examine the possibility to gain a significant anti-tumoral immune response and improvement in long term survival rates of HCC patients. Here, CCR2 is linked to hepatocellular carcinoma.